Drug Patents owned by Neurocrine

1. Drug name - INGREZZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8039627 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto
Oct, 2029

(7 years from now)

US10065952 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10851103 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10844058 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10851104 NEUROCRINE Valbenazine salts and polymorphs thereof
Oct, 2036

(14 years from now)

US10906902 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(14 years from now)

US10919892 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(14 years from now)

US10906903 NEUROCRINE Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1,-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
Dec, 2036

(14 years from now)

CN101553487A NEUROCRINE Substituted 3-Isobutyl-9,10-Dimethoxy-1,3,4,6,7,11B-Hexahydro-2H-Pyrido[2,1-A]Isoquinolin-2-Ol Compounds And Methods Relating Thereto
Nov, 2027

(5 years from now)

CN101553487B NEUROCRINE Substituted 3-Isobutyl - -9, 10 - -1, 3, 4, 6, 7, 11B-Hexahydro - -2H - Pyrido [2 1-A] -2 - Alcohol Compound And The Relative Method
Nov, 2027

(5 years from now)

IN200902647P1 NEUROCRINE Substituted 3-Isobutyl-9,10-Dimethoxy-1,3,4,6,7,11 B-Hexahydro-2H-Pyrido[2,1-A] Isoquinolin-2-Ol Compounds And Methods Relating Thereto
Nov, 2027

(5 years from now)

IN289479B NEUROCRINE A Substituted 3- Isobutyl-9,10- Dimethoxy-1,3,4,6,7,11 B-Hexahydro-2Hpyrido[ 2,1-A] Isoquinolin-2-Ol Compound
Nov, 2027

(5 years from now)

EP2081929A1 NEUROCRINE Substituted 3-Isobutyl-9, 10-Dimethoxy-1,3,4,6,7,11B-Hexahydro-2H-Pyrido[2,1-A]Isoquinolin-2-Ol Compounds And Methods Relating Thereto
Nov, 2027

(5 years from now)

EP2081929B1 NEUROCRINE Substituted 3-Isobutyl-9, 10-Dimethoxy-1,3,4,6,7,11B-Hexahydro-2H-Pyrido[2,1-A]Isoquinolin-2-Ol Compounds And Methods Relating Thereto
Nov, 2027

(5 years from now)

EP3368534B1 NEUROCRINE Valbenazine Ditosylate And Polymorphs Thereof
Oct, 2036

(14 years from now)

EP3368534A1 NEUROCRINE Valbenazine Ditosylate And Polymorphs Thereof
Oct, 2036

(14 years from now)

EP3394057B1 NEUROCRINE Synthetic Method For Preparation Of (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-A]Lsoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate)
Dec, 2036

(14 years from now)

EP3394057A1 NEUROCRINE Synthetic Method For Preparation Of (S)-(2R,3R,11Br)-3-Isobutyl-9,10-Dimethoxy-2,3,4,6,7,11B-Hexahydro-1H-Pyrido[2,1,-A]Lsoquinolin-2-Yl 2-Amino-3-Methylbutanoate Di(4-Methylbenzenesulfonate)
Dec, 2036

(14 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8357697 NEUROCRINE Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol compounds and methods relating thereto Nov, 2027

(5 years from now)

US10857148 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10952997 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10857137 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10874648 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10912771 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US11040029 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US10993941 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Oct, 2037

(15 years from now)

US11026939 NEUROCRINE High dosage valbenazine formulation and compositions, methods, and kits related thereto Sep, 2038

(15 years from now)

US11026931 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Aug, 2039

(16 years from now)

US10940141 NEUROCRINE Methods for the administration of certain VMAT2 inhibitors Aug, 2040

(17 years from now)

Drugs and Companies using VALBENAZINE TOSYLATE ingredient

Treatment: Treatment of tardive dyskinesia; Treatment of tardive dyskinesia; method of administering valbenazine while avoiding concomitant use of a strong cyp3a4 inducer; Method of treating tardive dyskinesia while avoiding concomitant use of a strong cyp3a4 inducer; treatment of tardive dyskinesia

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG BASE CAPSULE;ORAL Prescription
EQ 60MG BASE CAPSULE;ORAL Prescription
EQ 80MG BASE CAPSULE;ORAL Prescription

2. Drug name - ONGENTYS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8907099 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
May, 2027

(4 years from now)

US8168793 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors
Apr, 2029

(6 years from now)

US9630955 NEUROCRINE Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor
Dec, 2032

(10 years from now)

CN101248064B NEUROCRINE Nitrate Group Scatechol Derivative As Comt Inhibitor
Jul, 2026

(3 years from now)

CN102816157B NEUROCRINE Nitrate Group Scatechol Derivative As Comt Inhibitor
Jul, 2026

(3 years from now)

CN102816157A NEUROCRINE Nitrate Group Scatechol Derivative As Comt Inhibitor
Jul, 2026

(3 years from now)

CN101248064A NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2026

(3 years from now)

IN200801612P1 NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2026

(3 years from now)

IN268246B NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2026

(3 years from now)

IN201401357P3 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

IN326913B NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O- Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

EP1907382A1 NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2020

(2 years ago)

EP1907382B1 NEUROCRINE Nitrocatechol Derivatives As Comt Inhibitors
Jul, 2020

(2 years ago)

EP2791134B1 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

EP2791134A1 NEUROCRINE Chemical Compound Useful As Intermediate For Preparing A Catechol-O-Methyltransferase Inhibitor
Dec, 2032

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9550759 NEUROCRINE Nitrocatechol derivatives as COMT inhibitors Jul, 2026

(3 years from now)

US9745290 NEUROCRINE Dosage regimen for COMT inhibitors Oct, 2027

(5 years from now)

US8524746 NEUROCRINE Dosage regimen for COMT inhibitors Jul, 2029

(6 years from now)

US10071085 NEUROCRINE Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof Mar, 2030

(7 years from now)

US10583130 NEUROCRINE Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof Mar, 2030

(7 years from now)

US10357468 NEUROCRINE Medicaments for slowing Parkinson's disease May, 2035

(12 years from now)

Drugs and Companies using OPICAPONE ingredient

Treatment: Method of inhibiting comt in the periphery; method of treating parkinson's disease; method of reducing o-methylation of l-dopa; Method of treating parkinson's disease; Adjunctive treatment to levodopa/carbidopa in patients with parkinson's disease

Dosage: CAPSULE;ORAL

More Information on Dosage
Strength Dosage Availability
25MG CAPSULE;ORAL Prescription
50MG CAPSULE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.